242 related articles for article (PubMed ID: 22989705)
1. Pioglitazone protects against cisplatin induced nephrotoxicity in rats and potentiates its anticancer activity against human renal adenocarcinoma cell lines.
Mahmoud MF; El Shazly SM
Food Chem Toxicol; 2013 Jan; 51():114-22. PubMed ID: 22989705
[TBL] [Abstract][Full Text] [Related]
2. The peroxisome proliferator-activated receptor-γ agonist pioglitazone protects against cisplatin-induced renal damage in mice.
Jesse CR; Bortolatto CF; Wilhelm EA; Roman SS; Prigol M; Nogueira CW
J Appl Toxicol; 2014 Jan; 34(1):25-32. PubMed ID: 22987311
[TBL] [Abstract][Full Text] [Related]
3. Protective effect of peroxisome proliferator activator receptor (PPAR)-α and -γ ligands against methotrexate-induced nephrotoxicity.
Ibrahim MA; El-Sheikh AA; Khalaf HM; Abdelrahman AM
Immunopharmacol Immunotoxicol; 2014 Apr; 36(2):130-7. PubMed ID: 24521009
[TBL] [Abstract][Full Text] [Related]
4. Additive Renoprotection by Pioglitazone and Fenofibrate against Inflammatory, Oxidative and Apoptotic Manifestations of Cisplatin Nephrotoxicity: Modulation by PPARs.
Helmy MM; Helmy MW; El-Mas MM
PLoS One; 2015; 10(11):e0142303. PubMed ID: 26536032
[TBL] [Abstract][Full Text] [Related]
5. Peroxisome proliferator-activated receptor-gamma ligand reduced tumor necrosis factor-alpha-induced interleukin-8 production and growth in endometriotic stromal cells.
Ohama Y; Harada T; Iwabe T; Taniguchi F; Takenaka Y; Terakawa N
Fertil Steril; 2008 Feb; 89(2):311-7. PubMed ID: 17555752
[TBL] [Abstract][Full Text] [Related]
6. Pioglitazone ameliorates behavioral, biochemical and cellular alterations in quinolinic acid induced neurotoxicity: possible role of peroxisome proliferator activated receptor-Upsilon (PPARUpsilon) in Huntington's disease.
Kalonia H; Kumar P; Kumar A
Pharmacol Biochem Behav; 2010 Aug; 96(2):115-24. PubMed ID: 20450929
[TBL] [Abstract][Full Text] [Related]
7. The peroxisome proliferator-activated receptor γ agonist pioglitazone prevents NF-κB activation in cisplatin nephrotoxicity through the reduction of p65 acetylation via the AMPK-SIRT1/p300 pathway.
Zhang J; Zhang Y; Xiao F; Liu Y; Wang J; Gao H; Rong S; Yao Y; Li J; Xu G
Biochem Pharmacol; 2016 Feb; 101():100-11. PubMed ID: 26673543
[TBL] [Abstract][Full Text] [Related]
8. Rosiglitazone and 15-deoxy-Delta12,14-prostaglandin J2, ligands of the peroxisome proliferator-activated receptor-gamma (PPAR-gamma), reduce ischaemia/reperfusion injury of the gut.
Cuzzocrea S; Pisano B; Dugo L; Ianaro A; Patel NS; Di Paola R; Genovese T; Chatterjee PK; Di Rosa M; Caputi AP; Thiemermann C
Br J Pharmacol; 2003 Sep; 140(2):366-76. PubMed ID: 12970094
[TBL] [Abstract][Full Text] [Related]
9. Pioglitazone ameliorates nonalcoholic steatohepatitis by down-regulating hepatic nuclear factor-kappa B and cyclooxygenases-2 expression in rats.
Zhao JS; Zhu FS; Liu S; Yang CQ; Chen XM
Chin Med J (Engl); 2012 Jul; 125(13):2316-21. PubMed ID: 22882855
[TBL] [Abstract][Full Text] [Related]
10. Crosstalk between peroxisome proliferator-activated receptor-γ and mineralcorticoid receptor in TNF-α activated renal tubular cell.
Xiao J; Chen W; Lu Y; Zhang X; Fu C; Yan Z; Zhang Z; Ye Z
Inflamm Res; 2015 Aug; 64(8):603-14. PubMed ID: 26072064
[TBL] [Abstract][Full Text] [Related]
11. Involvement of glucocorticoid receptor and peroxisome proliferator activated receptor-gamma in pioglitazone mediated chronic gastric ulcer healing in rats.
Lahiri S; Sen T; Palit G
Eur J Pharmacol; 2009 May; 609(1-3):118-25. PubMed ID: 19281808
[TBL] [Abstract][Full Text] [Related]
12. Regulation of cigarette smoke-induced toll-like receptor 4 expression by peroxisome proliferator-activated receptor-gamma agonists in bronchial epithelial cells.
Yin Y; Hou G; Li ER; Wang QY; Kang J
Respirology; 2013 Nov; 18 Suppl 3():30-9. PubMed ID: 24188201
[TBL] [Abstract][Full Text] [Related]
13. Peroxisome proliferator-activated receptor-gamma ligands 15-deoxy-delta(12,14)-prostaglandin J2 and pioglitazone inhibit hydroxyl peroxide-induced TNF-alpha and lipopolysaccharide-induced CXC chemokine expression in neonatal rat cardiac myocytes.
Liu J; Xia Q; Zhang Q; Li H; Zhang J; Li A; Xiu R
Shock; 2009 Sep; 32(3):317-24. PubMed ID: 19174742
[TBL] [Abstract][Full Text] [Related]
14. Transcriptional regulation of nephrin gene by peroxisome proliferator-activated receptor-gamma agonist: molecular mechanism of the antiproteinuric effect of pioglitazone.
Benigni A; Zoja C; Tomasoni S; Campana M; Corna D; Zanchi C; Gagliardini E; Garofano E; Rottoli D; Ito T; Remuzzi G
J Am Soc Nephrol; 2006 Jun; 17(6):1624-32. PubMed ID: 16687628
[TBL] [Abstract][Full Text] [Related]
15. Explicit role of peroxisome proliferator-activated receptor gamma in gallic acid-mediated protection against ischemia-reperfusion-induced acute kidney injury in rats.
Singh JP; Singh AP; Bhatti R
J Surg Res; 2014 Apr; 187(2):631-9. PubMed ID: 24433871
[TBL] [Abstract][Full Text] [Related]
16. Renal protective effects of arjunolic acid in a cisplatin-induced nephrotoxicity model.
Elsherbiny NM; Eladl MA; Al-Gayyar MM
Cytokine; 2016 Jan; 77():26-34. PubMed ID: 26517155
[TBL] [Abstract][Full Text] [Related]
17. Protective effects of 6-hydroxy-1-methylindole-3-acetonitrile on cisplatin-induced oxidative nephrotoxicity via Nrf2 inactivation.
Moon JH; Shin JS; Kim JB; Baek NI; Cho YW; Lee YS; Kay HY; Kim SD; Lee KT
Food Chem Toxicol; 2013 Dec; 62():159-66. PubMed ID: 23989062
[TBL] [Abstract][Full Text] [Related]
18. Effects of peroxisome proliferator-activated receptors-gamma ligands on dextran sodium sulphate-induced colitis in rats.
Celinski K; Dworzanski T; Korolczuk A; Piasecki R; Slomka M; Madro A; Fornal R
J Physiol Pharmacol; 2011 Jun; 62(3):347-56. PubMed ID: 21893696
[TBL] [Abstract][Full Text] [Related]
19. Rosiglitazone ameliorates cisplatin-induced renal injury in mice.
Lee S; Kim W; Moon SO; Sung MJ; Kim DH; Kang KP; Jang YB; Lee JE; Jang KY; Park SK
Nephrol Dial Transplant; 2006 Aug; 21(8):2096-105. PubMed ID: 16728429
[TBL] [Abstract][Full Text] [Related]
20. Tetramethylpyrazine guards against cisplatin-induced nephrotoxicity in rats through inhibiting HMGB1/TLR4/NF-κB and activating Nrf2 and PPAR-γ signaling pathways.
Michel HE; Menze ET
Eur J Pharmacol; 2019 Aug; 857():172422. PubMed ID: 31152701
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
